Lexaria BioscienceLEXX -3.61%28 PB Ratio is 2.05 as of Jun. 25, 2026, which is 67% below its 10-year median of 6.17. GuruFocus rates LEXX with a GF Score™ of 28/100 and a GF Value™ of $0.75 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Lexaria Bioscience ranks better than 62.53% on this metric.
Lexaria Bioscience Corp stock PB Ratio (=2.05) is close to 2-year low of 2.04.
The historical rank and industry rank for Lexaria Bioscience's PB Ratio or its related term are showing as below:
LEXX'
s PB Ratio Range Over the Past 10 Years
Min: 0.9 Med: 6.17 Max: 64.87
Current: 2.05
During the past 13 years, Lexaria Bioscience's highest PB Ratio was 64.87. The lowest was 0.90. And the median was 6.17.
LEXX's PB Ratio is ranked better than 62.53% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs LEXX: 2.05
During the past 12 months, Lexaria Bioscience's average Book Value Per Share Growth Rate was -34.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -3.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lexaria Bioscience was 79.80% per year. The lowest was -66.10% per year. And the median was -14.10% per year.
Back to Basics: PB Ratio
Lexaria Bioscience (NAS:LEXX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lexaria Bioscience PB Ratio Related Terms
Lexaria Bioscience PB Ratio Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lexaria Bioscience (LEXX) has a PB Ratio of 2.05 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lexaria Bioscience and its competitors. This is 67% below median its historical median of 6.17. Over the past decade, Lexaria Bioscience's PB Ratio has ranged from 0.90 to 64.87. According to the industry distribution chart, Lexaria Bioscience ranks #462 out of 1233 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Lexaria Bioscience's PB Ratio too high?
Lexaria Bioscience's current PB Ratio of 2.05 is 67% below median its 10-year median of 6.17. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 64.87. The Biotechnology industry median PB Ratio is 2.80. Lexaria Bioscience's value of 2.05 is 26.8% below this industry median. Based on the distribution chart, Lexaria Bioscience ranks #462 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lexaria Bioscience has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's PB Ratio compare to MBRX and ICU?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #462 out of 1233 companies for PB Ratio. This puts Lexaria Bioscience in the upper half of its industry. The industry median PB Ratio is 2.80. Lexaria Bioscience's value of 2.05 is 26.8% below this benchmark. Historically, Lexaria Bioscience's own PB Ratio has ranged from 0.90 to 64.87 over the past decade. While the company's 10-year median is 6.17 vs. the industry median of 2.80, Lexaria Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current PB Ratio of 2.05 is 26.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current PB Ratio is 2.05, which is 67% below median its own 10-year median of 6.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.75, compared to a current price of $0.54 — trading 27.7% below its estimated fair value. The current PB Ratio is 2.05, which is 67% below median its 10-year median of 6.17 and 26.8% below the Biotechnology industry median of 2.80. Lexaria Bioscience's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current PB Ratio is 2.05 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued.
The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75.
GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.
Key valuation signals for LEXX:
PB Ratio: 2.05 (67% below median its 10-year median of 6.17)
GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
Industry Position: 26.8% below the Biotechnology median (#462 of 1233)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score
Get the complete analysis for LEXX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
